This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and
safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose
titration in treating breakthrough pain episodes in adult cancer patients receiving strong
opioid analgesic on a fixed-schedule as well as rescue medication for breakthrough pain.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.